Table 2 Treatment and outcomes
Overall (N = 20) | Single therapy (N = 11) | Combination therapy (N = 9) | P value | |
|---|---|---|---|---|
Duration of intravenous antibiotics, days (median [IQR]) | 6.00 [4.75;7.25] | 7.00 [4.50;12.5] | 5.00 [5.00;6.00] | 0.25 |
Duration of oral antibiotics, days (median [IQR]) | 34.0 [29.5;36.0] | 33.0 [27.0;35.5] | 36.0 [33.0;37.0] | 0.12 |
Total duration on antibiotics, days (median [IQR]) | 40.0 [38.0;41.5] | 40.0 [38.0;41.0] | 41.0 [38.0;43.0] | 0.76 |
Intravenous antibiotics used | ||||
Cefazoline (n, %) | 12 (60.0%) | 6 (54.5%) | 6 (66.7%) | 0.24 |
Amoxicillin (n, %) | 3 (15.0%) | 3 (27.3%) | 0 (0.00%) | |
Cloxacillin (n, %) | 2 (10.0%) | 0 | 2 (22.2%) | |
Vancomycin (n, %) | 2 (10%) | 1 (9%) | 1 (11.1%) | |
Daptomycin (n, %) | 1 (5.0%) | 1 (9%) | 0 | |
Switch to oral antibiotics (n, %) | 20 (100%) | 11 (100%) | 9 (100%) | 1.00 |
Oral antibiotics used | ||||
Levofloxacin (n, %) | 11 (55.0%) | 3 (27.3%) | 8 (88.9%) | 0.08 |
Clindamycin (n, %) | 9 (45.0%) | 5 (45.5%) | 4 (44.4%) | |
Amoxicillin (n, %) | 3 (15.0%) | 2 (18.2%) | 1 (11.1%) | |
Rifampin (n, %) | 3 (15.0%) | 0 | 3 (33.3%) | |
Doxycycline (n, %) | 1 (5.0%) | 0 | 1 (11.1%) | |
Linezolid (n, %) | 1 (5.0%) | 1 (9.09%) | 0 | |
Secondary adverse events imputed to antibiotics | 1 (5.00%) | 1 (11.1%) | 0 (0%) | |
Patients undergoing new surgical debridement (n, %) | 4 (20.0%) | 3 (27.3%) | 1 (11.1%) | 0.59 |
Delay between initial revision and new surgical debridement (days) (median [IQR]) | 20 [10.5 ; 114.8] | 12 [9 ; 20] | 376 | 0.5 |
Patients with microbiological failure (n, %) | 0 | 0 | 0 | |
Deaths from any cause at 1 year (n, %) | 1 (5.0%) | 0 | 1 (11.1%) | |
Primary endpoint (n, %) | 1 (5.0%) | 0 | 1 (11.1%) | |
Deaths from any cause during follow-up (n, %) | 2 (10.0%) | 0 | 2 (22.2%) | |
Duration of follow-up, days (median [IQR]) | 1024 [580;1512] | 862 [573;1157] | 1493 [699;1715] | 0.18 |